New European Study Shows TheraSphere® Prolongs Liver Cancer Survival Rates
07 10월 2010 - 7:15PM
Business Wire
MDS Nordion, a leading provider of products and services to the
global health science market, today announced that the first large
European study using Yttrium-90 (Y-90) glass microspheres has been
published on the use of TheraSphere®, an innovative
radioembolisation therapy for the localised treatment of patients
with advanced hepatocellular carcinoma (HCC) or primary liver
cancer. The publication, which currently can be viewed online and
is expected to appear in the November 2010 edition of Hepatology,
concludes that radioembolisation with TheraSphere® is both safe and
effective, and states that the overall survival rate is similar to
that found in another recently published large study analysing Y-90
glass microspheres for the treatment of HCC.1
In line with this announcement, MDS Nordion will attend the
European Association of Nuclear Medicine 2010 conference in Vienna,
9 to 13 October, booth X14-15, where a leading interventional
radiologist and nuclear medicine physician (a co-author of the
study) will discuss their experiences with the therapy and the
options it offers liver cancer patients.
Conducted at MDS Nordion’s European Centre of Excellence in
Essen, Germany, the study involved 108 patients, none of whom were
eligible for conventional locoregional therapies. Patients achieved
a median overall survival of 16.4 months with minimal damage to the
surrounding healthy tissue, even in patients with advanced liver
cirrhosis or portal vein thrombosis. No lung or visceral toxicity
was observed. The most frequently observed adverse event was a
transient fatigue-syndrome.
Philip Hilgard, MD, hepatologist and lead author of the paper
says, “The outcomes of this study were not unexpected, but it was
extremely important for us to be able to substantiate and verify
the treatment here in Europe. We feel confident that the
publication of our study will help towards giving more patients
access to this advanced therapy.” The full study, entitled
“Radioembolisation with Yttrium-90 Glass Microspheres in
Hepatocellular Carcinoma: European Experience on Safety and long
term Survival” is available online here.
Peter Covitz, Ph.D., Senior Vice President, Innovation, MDS
Nordion, comments, “The patient outcomes reported in this study
substantiate our belief that TheraSphere offers an important
therapy option for advanced liver cancer patients. We look forward
to working with more patients and oncologists to further advance
the quality of liver cancer treatment in Europe.”
Nadine Piorkowsky, President of the European Liver Patients
Association (ELPA) adds, “Radioactive microspheres that can be
targeted directly to the tumour via the arteries are a major
scientific breakthrough for interventional oncology. We
encourage further studies that will improve patient outcomes.”
At MDS Nordion’s booth at this year’s EANM conference, there
will be unique and educational presentations that will provide an
overview of radioembolisation using Y-90 for liver cancer patients,
including:
- Dr Riad Salem, Professor of Radiology,
Medicine and Surgery and Director of Interventional Oncology in the
Department of Radiology at Northwestern University, has been
leading a number of TheraSphere studies in the U.S. He will present
on specific case studies and experiences.
Spokespeople available for interviews relating to the study:
- Dr. Philip Hilgard, Associate Professor
of Medicine and Head of Department for Internal Medicine and
Gastroenterology at the Academic Teaching Hospital Evangelisches
Krankenhaus in Mülheim/Ruhr, Germany.
- Prof. Dr. med. Gerald Antoch, Director
of the Institute of Radiology at the University Hospital
Düsseldorf.
In-person interviews will be available with the following at
EANM:
- Dr Riad Salem
- Tom Burnett, Vice President Global
Sales, MDS Nordion
EANM booth location:Booth X14-15
About Primary Liver CancerAbout 50,000 cases of liver
cancer are diagnosed each year in the European Union, with 31,000
of those cases in Germany, Italy, Austria, UK and France, according
to the European Cancer Observatory (2008). Approximately, 600,000
cases are diagnosed each year globally. The most common form of
primary liver cancer is hepatocellular carcinoma. Hepatocellular
carcinoma is the fifth most common form of cancer in the world and
is increasing globally due to an increase in the incidence of
hepatitis.
About TheraSphereTheraSphere is a liver cancer therapy
that consists of millions of small glass beads (20 to 30
micrometers in diameter) containing radioactive yttrium-90. The
product is injected by physicians into the main artery of the
patient’s liver through a catheter, which allows the treatment to
be delivered directly to the tumour via blood vessels.
TheraSphere treatment can generally be administered on an
outpatient basis and does not usually require an overnight hospital
stay. MDS Nordion is approved (CE Mark) in Europe to distribute
TheraSphere for treatment of hepatic neoplasia. MDS Nordion
established a European TheraSphere Centre of Excellence in Essen,
Germany to train and educate oncology professionals on the use of
this innovative cancer treatment. In addition, there are multiple
treatment centres across Europe, including the BCLC Group Hospital
Clinic in Barcelona, Spain; Centre Eugene Marquis in Rennes,
France; and Istituto Tumori in Milan, Italy.
TheraSphere treatment has some common side effects, including
mild to moderate fatigue, pain and nausea for about a week.
Physicians describe these symptoms as similar to those of the
common flu. Some patients will experience some loss of appetite and
temporary changes in several blood tests. For details on the rarer
side effects, please refer to the Instructions for Use on our
website at www.mdsnordion.com/TheraSphere.
About MDS Inc.MDS Inc. (TSX: MDS) (NYSE: MDZ) is a global
health science company that provides market-leading products and
services used for the prevention, diagnosis and treatment of
disease. We are a leading provider of innovative technologies for
use in medical imaging and radiotherapeutics, and sterilization
technologies benefiting the lives of millions of people in more
than 65 countries around the world. Our products and services are
used daily by pharmaceutical and biotechnology companies,
medical-device manufacturers, hospitals, clinics and research
laboratories. MDS has more than 600 highly skilled employees in
four locations. Find out more at www.mdsnordion.com.
1 Gastroenterology 2010; 138: 52-64.
Mds (NYSE:MDZ)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Mds (NYSE:MDZ)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
